Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

White House, Allergan Spar Over 'Un-American' Claim

This article was originally published in Scrip

Executive Summary

The White House on April 6 fought back against accusations from Allergan PLC CEO Brent Saunders the Obama administration's move to institute new rules aimed at thwarting corporate inversion was "un-American" and had specifically been constructed to take down the company's $160bn merger deal with Pfizer Inc., which had, indeed, fallen apart in light of the US Treasury Department's actions.

You may also be interested in...



Allergan's Fishing For Deals, But Don't Expect A Big Catch

Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.

Pfizer Split, Once Decided, Could Happen Quickly, CEO Says

Pfizer Inc. could complete a business breakup in about one year if the company decides to move forward with a split, CEO Ian Read said during the company’s first quarter sales and earnings call May 3.

Moderna's Valera Takes mRNA Approach To Combat Zika

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel